tldrdaily.news logo

GSK's Checkpoint Inhibitor and Chemotherapy Combo Improves Survival in Endometrial Cancer

1 min read
Source: Endpoints News
GSK's Checkpoint Inhibitor and Chemotherapy Combo Improves Survival in Endometrial Cancer
Photo: Endpoints News
TL;DR Summary

GSK's checkpoint inhibitor, Jemperli, when added to chemotherapy, has been found to prolong the survival of patients with advanced or recurrent endometrial cancer in a Phase III study. The study met its primary overall survival endpoint, with patients receiving Jemperli-chemo treatment living longer than those in the comparator arm.

Topics:business#checkpoint-inhibitor#chemotherapy#clinical-trial#endometrial-cancer#gsk#healthcare
Share this article
  1. GSK’s checkpoint inhibitor plus chemotherapy prolongs survival for endometrial cancer patients in PhIII study  Endpoints News
  2. Dostarlimab Plus Chemo Provides OS Benefit in Primary Advanced or Recurrent Endometrial Cancer  OncLive
  3. In industry first, GSK's PD-1 trial hits overall survival goal  FiercePharma
  4. GSK's cancer drug Jemperli meets overall survival goal in late-stage trial  Reuters
  5. Dr Mirza on the Use of Dostarlimab/Chemotherapy By Molecular Class in Endometrial Cancer  OncLive
  6. View Full Coverage on Google News

Reading Insights

Total Reads

0

Unique Readers

1

Time Saved

0 min

vs 1 min read

Condensed

55%

110 → 49 words

Want the full story? Read the original article

Read on Endpoints News